Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Mol Clin Oncol
2014 Nov 01;26:953-959. doi: 10.3892/mco.2014.359.
Show Gene links
Show Anatomy links
Rechallenge with pemetrexed-based chemotherapy improves the survival of patients with advanced non-squamous non-small-cell lung cancer.
Zhuo ML
,
Bai H
,
Wang ZJ
,
Duan JC
,
An TT
,
Wu MN
,
Zhao J
,
Wang YY
,
Wang SH
,
Wang J
.
???displayArticle.abstract???
Rechallenge chemotherapy with pemetrexed was shown to be efficient in malignant pleural mesothelioma; however, its role in non-small-cell lung cancer (NSCLC) has not been investigated. In this study, we retrospectively enrolled 31 patients with non-squamous NSCLC who had achieved disease control with initial pemetrexed treatment, followed by rechallenge with pemetrexed-based chemotherapy (PBC) upon disease progression. After the rechallenge, 5 patients (16.1%) achieved partial remission (PR), 17 (54.8%) achieved stable disease (SD) and 9 (29.1%) experienced progressive disease. The treatment was generally well tolerated, with a low rate of toxicity. The median progression-free survival (PFS) was 3.8 months with the rechallenge. Patients with a PFS of ≥10 months with initial PBC exhibited longer PFS and overall survival (OS) with the rechallenge compared to those with a PFS of <10 months with initial PBC (PFS: 6.2±0.33 vs. 3.1±0.26 months, respectively; P=0.011; and OS, 19.8±3.2 vs. 9.2±1.1 months, respectively; P=0.005). The time from the termination of initial PBC to disease progression was also associated with survival after the rechallenge. However, the response to initial PBC (PR vs. SD) did not affect PFS after the rechallenge. No significant differences were observed in thymidylate synthase expression, echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase gene fusion, or epithelial growth factor receptor mutation status between pemetrexed-sensitive and pemetrexed-resistant patients. Our results demonstrated that rechallenge with PBC was well tolerated and survival after the rechallenge was associated with survival during initial PBC. Therefore, patients with a PFS of ≥10 months or time-to-disease progression ≥3 months may be considered as candidates for pemetrexed rechallenge.
Bai,
Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer.
2012, Pubmed
Bai,
Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer.
2012,
Pubmed
Barlesi,
Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089).
2013,
Pubmed
Bearz,
Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience.
2012,
Pubmed
Ceresoli,
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.
2011,
Pubmed
Chen,
Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.
2011,
Pubmed
Christoph,
Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma.
2012,
Pubmed
Eisenhauer,
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
2009,
Pubmed
Garassino,
Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.
2011,
Pubmed
Hanna,
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.
2004,
Pubmed
Kawano,
Pemetrexed and cisplatin for advanced non-squamous non-small cell lung cancer in Japanese patients: phase II study.
2013,
Pubmed
Monica,
Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung.
2009,
Pubmed
Paz-Ares,
PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
2013,
Pubmed
Pfisterer,
Management of platinum-sensitive recurrent ovarian cancer.
2006,
Pubmed
Scagliotti,
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
2008,
Pubmed
Vogelzang,
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
2003,
Pubmed
Xu,
Pemetrexed as the first-line therapy for Chinese patients with advanced non-squamous non-small-cell lung cancer.
2013,
Pubmed
Zucali,
Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
2012,
Pubmed